ATE209626T1 - Alkyloxyamin-substituierte fluorenonderivate und ihre verwendung als proteinkinase-c-inhibitoren - Google Patents

Alkyloxyamin-substituierte fluorenonderivate und ihre verwendung als proteinkinase-c-inhibitoren

Info

Publication number
ATE209626T1
ATE209626T1 AT97921288T AT97921288T ATE209626T1 AT E209626 T1 ATE209626 T1 AT E209626T1 AT 97921288 T AT97921288 T AT 97921288T AT 97921288 T AT97921288 T AT 97921288T AT E209626 T1 ATE209626 T1 AT E209626T1
Authority
AT
Austria
Prior art keywords
alkyloxyamine
inhibitors
protein kinase
fluorenone derivatives
substituted fluorenone
Prior art date
Application number
AT97921288T
Other languages
English (en)
Inventor
Winton D Jones
Fred L Ciske
Robert J Dinerstein
Keith A Diekema
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27096988&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE209626(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of ATE209626T1 publication Critical patent/ATE209626T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/24—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes
AT97921288T 1996-05-30 1997-04-24 Alkyloxyamin-substituierte fluorenonderivate und ihre verwendung als proteinkinase-c-inhibitoren ATE209626T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65558496A 1996-05-30 1996-05-30
US65553796A 1996-05-30 1996-05-30
PCT/US1997/006602 WO1997045397A1 (en) 1996-05-30 1997-04-24 Alkyloxyamino substituted fluorenones and their use as protein kinase c inhibitors

Publications (1)

Publication Number Publication Date
ATE209626T1 true ATE209626T1 (de) 2001-12-15

Family

ID=27096988

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97921288T ATE209626T1 (de) 1996-05-30 1997-04-24 Alkyloxyamin-substituierte fluorenonderivate und ihre verwendung als proteinkinase-c-inhibitoren

Country Status (18)

Country Link
EP (1) EP0906268B1 (de)
JP (1) JP3897363B2 (de)
CN (1) CN1160309C (de)
AR (1) AR008375A1 (de)
AT (1) ATE209626T1 (de)
AU (1) AU737073B2 (de)
BR (1) BR9709406B1 (de)
CA (1) CA2257136C (de)
DE (1) DE69708629T2 (de)
DK (1) DK0906268T3 (de)
ES (1) ES2170390T3 (de)
HK (1) HK1019147A1 (de)
HU (1) HUP9901621A3 (de)
IL (1) IL126873A (de)
NO (1) NO312457B1 (de)
NZ (1) NZ332597A (de)
PT (1) PT906268E (de)
WO (1) WO1997045397A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103713A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for autoimmune diseases
US6103712A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for asthma
DE19908504C2 (de) * 1999-02-26 2003-04-30 Boehringer Ingelheim Pharma Großtechnisches Verfahren zur Herstellung von Derivaten der Biphenyl-2-carbonsäure durch Verseifen eines (2-Oxazolinyl)-2-biphenyl-Derivats mit Salzsäure
DE19917990A1 (de) * 1999-04-20 2000-11-02 Florian Lang Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk
EP1309563B1 (de) 2000-08-18 2005-05-11 Agouron Pharmaceuticals, Inc. Heterozyklische-hydroximino-fluorene und ihre verwendung zur inhibierung von proteinkinasen
US7365193B2 (en) 2004-02-04 2008-04-29 Abbott Laboratories Amino-substituted tricyclic derivatives and methods of use
US20050171079A1 (en) * 2004-02-04 2005-08-04 Schrimpf Michael R. Amino-substituted tricyclic derivatives and methods of use
RU2012133148A (ru) * 2010-01-11 2014-02-20 Хилор Лтд. Способ лечения воспалительного заболевания и расстройства
CN103204781B (zh) * 2013-03-14 2015-04-01 武汉大学 2,7–二取代芴酮衍生物及其制备方法与应用
CN109053435A (zh) * 2018-08-03 2018-12-21 上海华堇生物技术有限责任公司 2,3-二甲氧基苯甲酰氯的制备方法
CN115590964A (zh) * 2022-09-14 2023-01-13 苏州大学（Cn） 蛋白激酶c抑制剂在制备抗肿瘤转移药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL33573A (en) * 1968-12-30 1973-10-25 Richardson Merrell Inc Bis-basic ethers and thioethers of fluorenone,fluorenol and fluorene
US5034384A (en) * 1990-08-01 1991-07-23 Merck & Co., Inc. 2-(9-fluorenonyl)-carbapenem antibacterial agents

Also Published As

Publication number Publication date
AR008375A1 (es) 2000-01-19
JP3897363B2 (ja) 2007-03-22
NO985577D0 (no) 1998-11-27
DK0906268T3 (da) 2002-03-18
HUP9901621A3 (en) 2002-01-28
ES2170390T3 (es) 2002-08-01
CN1160309C (zh) 2004-08-04
AU737073B2 (en) 2001-08-09
BR9709406A (pt) 1999-08-10
PT906268E (pt) 2002-05-31
CA2257136C (en) 2004-07-20
HUP9901621A2 (hu) 1999-08-30
CA2257136A1 (en) 1997-12-04
NO312457B1 (no) 2002-05-13
WO1997045397A1 (en) 1997-12-04
EP0906268A1 (de) 1999-04-07
CN1220660A (zh) 1999-06-23
EP0906268B1 (de) 2001-11-28
BR9709406B1 (pt) 2009-05-05
NO985577L (no) 1999-01-27
IL126873A (en) 2005-09-25
IL126873A0 (en) 1999-09-22
NZ332597A (en) 2000-08-25
JP2000511528A (ja) 2000-09-05
DE69708629T2 (de) 2002-08-01
DE69708629D1 (de) 2002-01-10
AU2736597A (en) 1998-01-05
HK1019147A1 (en) 2000-01-14

Similar Documents

Publication Publication Date Title
ATE268761T1 (de) Substituierte quinazolin-derivate und ihre verwendung als tyrosin-kinase inhibitoren
DE69836346D1 (de) Heteroaryl aminoguanidin- und alkoxyguanidinderivate und ihre verwendung als proteasehemmer
ATE202347T1 (de) Aminothiophencarbonsäureamide und ihre verwendung als phosphodiesterase inhibitoren
DE69332898T2 (de) 4-Carboxamidopiperidinderivate und ihre Verwendung als Neurokinin Antagonisten
DE59712887D1 (de) Substituierte phenylketoenole und ihre verwendung als schädlingsbekämpfungsmittel
DE69627179D1 (de) Substituierte 2-anilino-pyrimidines verwendbar als protein kinase inhibitoren
DE69826662D1 (de) 4-brom or 4-iod-phenylamino-benzhydroxamsäurederivate und ihre anwendung als mek-inhibitoren
DE59710422D1 (de) Acylmercapto-triazolyl-derivate und ihre verwendung als mikrobizide
DE69734149D1 (de) Cinoline derivate und verwendung als heilmittel
ATE302193T1 (de) Benzoheterozyklen und ihre verwendung als mek inhibitoren
DE69826693D1 (de) Amidinoderivate und ihre verwendung als thrombininhibitoren
ATE205836T1 (de) Bicyclische 4-aralkylaminopyrimidin-derivate als tyrosinkinase-inhibitoren
DE69610316T2 (de) Piperazin-derivate und ihre verwendung als 5-ht1a-antagoniste
ATE209626T1 (de) Alkyloxyamin-substituierte fluorenonderivate und ihre verwendung als proteinkinase-c-inhibitoren
DE69510228T2 (de) Piperidinessigsäurederivate und ihre verwendung als fibrinogenantagonistmittel
ATE253059T1 (de) Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2- one und ihre verwendung als lipase-hemmer
DE69821988D1 (de) Substituierte isochinoline derivate und ihre verwendung als anticonvulsiva
ATE229016T1 (de) Substituierte heterocyclische benzocycloalkene und ihre verwendung als analgetisch wirksame substanzen
DE69732095D1 (de) Ionomerzusammensetzung und ihre verwendung
DE60008539D1 (de) Substituierte isochinolinderivate und ihre verwendung als anticonvulsiva
DE69718850D1 (de) Heterocyclische N-Acetonylbenzamide und ihre Verwendung als Fungizide
DE69623941D1 (de) Phenyl derivate und ihre verwendung als endothelin rezeptor
DE69707602D1 (de) Substituierte Vinylharnstoff-Derivate und ihre Verwendung als ACAT-Inhibitoren
DE69637431D1 (de) Ungen und ihre verwendung
DE59707610D1 (de) Substituierte carbamoyltriazole und ihre verwendung als herbizide

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner